Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 560 participants.

Also called NCT02227875

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 560 participants (enrolled count) (from the registry)
Sponsor
Mylan Inc. (from the registry)
Registry
  • NCT NCT02227875
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Jordan, Slovakia, South Africa, South Korea, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02227875. Randomized; no masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2015-12 (actual). Results posted on 2020-08-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)
Acronym
INSTRIDE 2
Intervention (Drug)
Mylan's insulin glargine
Intervention (Drug)
Lantus®
Lead sponsor
Mylan Inc. (class: industry)
Collaborator
Mylan GmbH (class: industry)

Record details

Record id
cardio:ct-nct02227875
Content hash
ae12d6659a81b84031caca664d96c9c4934d58449bcf39b116a1377a33a7afa6